PL3407888T3 - Związki pirydopirolochinoksaliny, ich kompozycje i zastosowania - Google Patents

Związki pirydopirolochinoksaliny, ich kompozycje i zastosowania

Info

Publication number
PL3407888T3
PL3407888T3 PL17744910T PL17744910T PL3407888T3 PL 3407888 T3 PL3407888 T3 PL 3407888T3 PL 17744910 T PL17744910 T PL 17744910T PL 17744910 T PL17744910 T PL 17744910T PL 3407888 T3 PL3407888 T3 PL 3407888T3
Authority
PL
Poland
Prior art keywords
pyridopyrroloquinoxaline
compositions
compounds
pyridopyrroloquinoxaline compounds
Prior art date
Application number
PL17744910T
Other languages
English (en)
Inventor
Wei Yao
Peng Li
Original Assignee
Intra-Cellular Therapies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra-Cellular Therapies, Inc. filed Critical Intra-Cellular Therapies, Inc.
Publication of PL3407888T3 publication Critical patent/PL3407888T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
PL17744910T 2016-01-26 2017-01-26 Związki pirydopirolochinoksaliny, ich kompozycje i zastosowania PL3407888T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662287264P 2016-01-26 2016-01-26
US201662440130P 2016-12-29 2016-12-29
PCT/US2017/015178 WO2017132408A1 (en) 2016-01-26 2017-01-26 Organic compounds
EP17744910.5A EP3407888B1 (en) 2016-01-26 2017-01-26 Pyridopyrroloquinoxaline compounds, their compositions and uses

Publications (1)

Publication Number Publication Date
PL3407888T3 true PL3407888T3 (pl) 2021-08-30

Family

ID=59398657

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20215786.3T PL3838274T3 (pl) 2016-01-26 2017-01-26 Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
PL17744910T PL3407888T3 (pl) 2016-01-26 2017-01-26 Związki pirydopirolochinoksaliny, ich kompozycje i zastosowania

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL20215786.3T PL3838274T3 (pl) 2016-01-26 2017-01-26 Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN

Country Status (17)

Country Link
US (3) US10245260B2 (pl)
EP (2) EP3407888B1 (pl)
JP (3) JP6995761B2 (pl)
KR (1) KR20180099905A (pl)
CN (2) CN108883111B (pl)
AU (1) AU2017211791B2 (pl)
BR (1) BR112018015283B1 (pl)
CA (1) CA3011983A1 (pl)
DK (2) DK3407888T3 (pl)
ES (1) ES2863471T3 (pl)
HU (1) HUE053737T2 (pl)
IL (3) IL260653B2 (pl)
MX (2) MX2018009158A (pl)
PL (2) PL3838274T3 (pl)
PT (2) PT3838274T (pl)
RU (1) RU2743513C2 (pl)
WO (1) WO2017132408A1 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102105059B (zh) * 2008-05-27 2015-09-30 细胞内治疗公司 用于睡眠障碍和其他疾病的方法和组合物
US11053245B2 (en) 2012-04-14 2021-07-06 Intra-Cellular Therapies, Inc. Methods
PT2968320T (pt) 2013-03-15 2021-01-28 Intra Cellular Therapies Inc Compostos orgânicos
EP3666271A1 (en) 2013-12-03 2020-06-17 Intra-Cellular Therapies, Inc. Miscrospheres comprising a plga matrix for medical use
EP3125893B1 (en) 2014-04-04 2023-09-20 Intra-Cellular Therapies, Inc. Deuterated heterocycle fused gamma-carbolines as antagonists of 5-ht2a receptors
EP3407888B1 (en) 2016-01-26 2020-12-30 Intra-Cellular Therapies, Inc. Pyridopyrroloquinoxaline compounds, their compositions and uses
EP3888656A1 (en) 2016-03-25 2021-10-06 Intra-Cellular Therapies, Inc. Deuterated heterocyclic gamma-carboline compounds and their use in the treatment or prophylaxis of a central nervous system disorder
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
JP7013454B2 (ja) 2016-10-12 2022-02-15 イントラ－セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
WO2018126140A1 (en) * 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126143A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
MX2021013640A (es) 2017-03-24 2022-08-31 Intra Cellular Therapies Inc Composiciones novedosas y metodos.
JP7224333B2 (ja) 2017-07-26 2023-02-17 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
CA3071119A1 (en) * 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. Organic compounds
US20210009592A1 (en) * 2018-03-23 2021-01-14 Intra-Cellular Therapies, Inc. Organic compounds
CN112040940A (zh) * 2018-03-23 2020-12-04 细胞内治疗公司 有机化合物
EP3801527A4 (en) * 2018-06-08 2022-03-30 Intra-Cellular Therapies, Inc. NEW METHODS
WO2019241278A1 (en) 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
CA3108558A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
MX2021007141A (es) * 2018-12-17 2021-08-11 Intra Cellular Therapies Inc Sintesis de gamma-carbolinas fusionadas con heterociclo sustituido.
KR20210104834A (ko) * 2018-12-17 2021-08-25 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로사이클 융합 감마-카르볼린 합성
BR112021011792A2 (pt) * 2018-12-17 2021-08-31 Intra-Cellular Therapies, Inc. Composto orgânico
WO2020132605A1 (en) * 2018-12-21 2020-06-25 Intra-Cellular Therapies, Inc. Organic compounds
JP7377871B2 (ja) 2018-12-21 2023-11-10 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
CA3125777A1 (en) * 2019-01-23 2020-07-30 Intra-Cellular Therapies, Inc. Methods of treating addiction
CA3134674A1 (en) * 2019-04-04 2020-10-08 Intra-Cellular Therapies, Inc. Methods of treating neuropathic pain
JP2022549335A (ja) * 2019-09-25 2022-11-24 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
WO2021119334A1 (en) 2019-12-11 2021-06-17 Intra-Cellular Therapies, Inc. Organic compound
KR20230054417A (ko) * 2020-10-09 2023-04-24 슈징 바이오파마 컴퍼니 리미티드 헤테로사이클로로 치환된 융합 γ-카르볼린 유도체, 이의 제조 방법, 중간체 및 용도

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2490813A (en) 1944-11-29 1949-12-13 Standard Oil Co Continuous process for making aryl amines
US3299078A (en) 1962-10-01 1967-01-17 Smith Kline French Lab Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines
US3813392A (en) 1969-06-09 1974-05-28 J Sellstedt Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds
US3914421A (en) 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
US4238607A (en) 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
US4183936A (en) 1972-06-19 1980-01-15 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4115577A (en) 1972-06-19 1978-09-19 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4001263A (en) 1974-04-01 1977-01-04 Pfizer Inc. 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines
IE41352B1 (en) 1974-04-01 1979-12-19 Pfizer 5-aryl-1,2,3,4-tetrahydro- -carbolines
US4136145A (en) 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
US4219550A (en) 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4522944A (en) 1982-12-23 1985-06-11 Erba Farmitalia Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use
SE8304361D0 (sv) 1983-08-10 1983-08-10 Ferrosan Ab Novel 1-acylpiperazine derivatives novel 1-acylpiperazine derivatives
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
EP0283474A1 (de) 1985-10-09 1988-09-28 Desitin Arzneimittel GmbH Verfahren zur herstellung einer darreichungs- und dosierungsform für arzneimittelwirkstoffe, reagentien oder andere wirkstoffe
ATE90683T1 (de) 1986-03-19 1993-07-15 Kumiai Chemical Industry Co 5h-1,3,4-thiazol(3,2-a>pyrimidin-5-on-derivate und diese enthaltende fungizide zubereitungen.
ATE91129T1 (de) 1986-04-07 1993-07-15 Kumiai Chemical Industry Co 5h-1,3,4-thiadiazolo(3,2-a>pyrimidin-5-onderivate und diese enthaltende gartenbau- und landwirtschaftliche fungizidmittel.
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
DE4018247A1 (de) 1990-06-07 1991-12-12 Lohmann Therapie Syst Lts Herstellungsverfahren fuer schnellzerfallende folienfoermige darreichungsformen
IT1271352B (it) 1993-04-08 1997-05-27 Boehringer Ingelheim Italia Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
ES2236700T3 (es) 1993-11-19 2005-07-16 Janssen Pharmaceutica N.V. 1,2-benzazoles microencapsulados.
PL180465B1 (pl) 1994-03-02 2001-02-28 Akzo Nobel Nv Kompozycja farmaceutyczna zawierajaca trans-5-chloro-2-metylo-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oksepino[4,5-c]pirol PL PL PL
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5576460A (en) 1994-07-27 1996-11-19 Massachusetts Institute Of Technology Preparation of arylamines
US5654482A (en) 1996-02-29 1997-08-05 Xerox Corporation Triarylamine processes
US5648539A (en) 1996-02-29 1997-07-15 Xerox Corporation Low temperature arylamine processes
US5648542A (en) 1996-02-29 1997-07-15 Xerox Corporation Arylamine processes
US5847166A (en) 1996-10-10 1998-12-08 Massachusetts Institute Of Technology Synthesis of aryl ethers
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
US5723671A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
US5705697A (en) 1997-01-30 1998-01-06 Xerox Corporation Arylamine processes
US5723669A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
TWI242011B (en) 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
GB2328686B (en) 1997-08-25 2001-09-26 Sankio Chemical Co Ltd Method for producing arylamine
US6395939B1 (en) 1997-10-06 2002-05-28 Massachusetts Institute Of Technology Diaryl ether condensation reactions
US6235936B1 (en) 1998-02-26 2001-05-22 Massachusetts Institute Of Technology Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates
JP4647780B2 (ja) 1998-02-26 2011-03-09 マサチューセッツ インスティテュート オブ テクノロジー ヒドラジン、ヒドラゾン、ヒドロキシルアミンおよびオキシムの金属−触媒アリール化およびビニル化
US5902901A (en) 1998-05-07 1999-05-11 Xerox Corporation Arylamine processes
US7223879B2 (en) 1998-07-10 2007-05-29 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US6395916B1 (en) 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US6307087B1 (en) 1998-07-10 2001-10-23 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
DK1097158T3 (da) 1998-07-10 2006-05-29 Massachusetts Inst Technology Ligander til metaller og metalkatalyserede metoder
US20010008942A1 (en) 1998-12-08 2001-07-19 Buchwald Stephen L. Synthesis of aryl ethers
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
ATE260642T1 (de) 1998-12-17 2004-03-15 Alza Corp Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6407092B1 (en) 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
PE20010052A1 (es) 1999-04-23 2001-01-27 Upjohn Co Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht
US6552017B1 (en) 1999-06-15 2003-04-22 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) * 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
PT1104760E (pt) 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
US6541639B2 (en) 2000-07-26 2003-04-01 Bristol-Myers Squibb Pharma Company Efficient ligand-mediated Ullmann coupling of anilines and azoles
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
RU2003121304A (ru) 2000-12-20 2005-01-27 Бристол-Маерс Сквибб Компани (Us) Замещенные пиридоиндолы в качестве агонистов и антагонистов серотонина
EP1390340B1 (en) 2001-04-24 2017-03-01 Massachusetts Institute Of Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
JP2005526691A (ja) 2001-08-08 2005-09-08 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 治療剤１Ｈ−ピリド［４，３−ｂ］インドール
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
EP1314554A1 (fr) 2001-11-23 2003-05-28 Kba-Giori S.A. Dispositif de décollage d'éléments de sécurité
PT1539115E (pt) 2002-07-29 2008-01-14 Alza Corp Métodos e formas de dosagem para libertação controlada de paliperidona
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
KR20050032107A (ko) 2002-08-02 2005-04-06 메사추세츠 인스티튜트 오브 테크놀로지 구리를 촉매로 한 탄소-헤테로원자 결합 및 탄소-탄소결합 형성방법
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
WO2004041281A1 (en) 2002-11-01 2004-05-21 Oregon Health And Science University Treatment of hyperkinetic movement disorder with donepezil
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
US7109339B2 (en) 2002-12-19 2006-09-19 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
US7462641B2 (en) 2003-07-21 2008-12-09 Smithkline Beecham Corporation (2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof
US7109064B2 (en) 2003-12-08 2006-09-19 Semiconductor Components Industries, L.L.C. Method of forming a semiconductor package and leadframe therefor
JP2005259113A (ja) 2004-02-12 2005-09-22 Ricoh Co Ltd プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法
CA2564018A1 (en) 2004-03-05 2005-10-13 Pharma C S.A. 8-phenoxy-.gamma. carboline derivatives
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US7592454B2 (en) 2004-04-14 2009-09-22 Bristol-Myers Squibb Company Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
DE602005027714D1 (de) 2004-09-20 2011-06-09 Sinai School Medicine Verwendung von memantin (namenda) zur behandlung von autismus, zwangsverhalten und impulsivität
CA2581023A1 (en) 2004-09-21 2006-03-30 Pfizer Products Inc. N-methyl hydroxyethylamine useful in treating cns conditions
US7614727B2 (en) 2004-09-30 2009-11-10 Fujifilm Corporation Liquid ejection head, manufacturing method thereof, and image forming apparatus
RU2007121768A (ru) 2004-12-15 2009-01-27 Ф. Хоффманн-Ля Рош Аг (Ch) Би- и трициклически замещенные фенилметаноны в качестве ингибиторов переносчика глицина 1 (glyt-1) для лечения болезни альцгеймера
JP2008528514A (ja) 2005-01-25 2008-07-31 セルジーン・コーポレーション ４−アミノ−２−（３−メチル−２，６−ジオキソピペリジン−３−イル）−イソインドール−１，３−ジオンを使用する方法及び組成物
US20080194592A1 (en) 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
CA2624179A1 (en) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
CA2636007A1 (en) 2006-01-13 2007-07-26 Wyeth Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
KR101805914B1 (ko) 2007-03-12 2017-12-06 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
WO2009017836A1 (en) 2007-08-01 2009-02-05 Medivation Neurology, Inc. Methods and compositions for treating schizophrenia using antipsychotic combination therapy
US8486973B2 (en) 2007-08-02 2013-07-16 Insys Therapeutics, Inc. Sublingual fentanyl spray
WO2009023253A2 (en) 2007-08-15 2009-02-19 Arena Pharmaceuticals Inc. IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
US20090209608A1 (en) 2007-08-29 2009-08-20 Protia, Llc Deuterium-enriched asenapine
US20090076159A1 (en) 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched eplivanserin
EP2262502A4 (en) 2008-02-05 2011-12-28 Clera Inc COMPOSITIONS AND METHODS FOR RELIEVING DEPRESSION OR ENHANCING COGNITIVE PROCESSES
MX2010008688A (es) 2008-02-07 2010-08-30 Schering Corp Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria.
KR20150140418A (ko) 2008-03-12 2015-12-15 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로사이클 융합 감마-카볼라인 고체
CN102105059B (zh) 2008-05-27 2015-09-30 细胞内治疗公司 用于睡眠障碍和其他疾病的方法和组合物
US8309772B2 (en) 2008-07-31 2012-11-13 Celanese International Corporation Tunable catalyst gas phase hydrogenation of carboxylic acids
US20100159033A1 (en) 2008-09-29 2010-06-24 Auspex Pharmaceuticals, Inc. Benzisoxazole modulators of d2 receptor, and/or 5-ht2a receptor
US8778893B2 (en) 2009-10-05 2014-07-15 Bristol-Myers Squibb Company (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol metabolites
CN102762575B (zh) * 2009-12-04 2015-04-15 桑诺维恩药品公司 多环化合物及其使用方法
US8993572B2 (en) 2010-04-22 2015-03-31 Intra-Cellular Therapies, Inc. Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives
TWI582092B (zh) 2010-07-28 2017-05-11 歌林達股份有限公司 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物
KR101890317B1 (ko) 2010-12-16 2018-08-22 선오비온 파마슈티컬스 인코포레이티드 설하 필름
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
US20140220134A1 (en) 2011-06-24 2014-08-07 Astrazeneca Pharamceuticals LP Method for treating diabetes with extended release formulation of glp-1 receptor agonists
US11053245B2 (en) 2012-04-14 2021-07-06 Intra-Cellular Therapies, Inc. Methods
WO2014005194A1 (en) 2012-07-06 2014-01-09 The University Of Melbourne Immunological reagents and uses therefor
IN2015DN02070A (pl) 2012-09-14 2015-08-14 Abbvie Deutschland
PT2968320T (pt) 2013-03-15 2021-01-28 Intra Cellular Therapies Inc Compostos orgânicos
DK3043777T3 (da) 2013-09-10 2020-07-20 Fresh Cut Dev Llc Sublingual buprenorphinspray
EP3666271A1 (en) 2013-12-03 2020-06-17 Intra-Cellular Therapies, Inc. Miscrospheres comprising a plga matrix for medical use
EP3125892A4 (en) 2014-04-04 2017-12-27 Intra-Cellular Therapies, Inc. Organic compounds
EP3125893B1 (en) 2014-04-04 2023-09-20 Intra-Cellular Therapies, Inc. Deuterated heterocycle fused gamma-carbolines as antagonists of 5-ht2a receptors
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
CA2987114A1 (en) 2015-06-03 2016-12-08 Triastek, Inc. Method of 3d printing oral dosage forms having a drug in a compartment sealed by an erodibleplug
WO2017117514A1 (en) 2015-12-31 2017-07-06 Tung Roger D Deuterated iti-007
EP3407888B1 (en) 2016-01-26 2020-12-30 Intra-Cellular Therapies, Inc. Pyridopyrroloquinoxaline compounds, their compositions and uses
WO2017165755A1 (en) 2016-03-25 2017-09-28 Intra-Cellular Therapies, Inc. Organic compounds
EP3888656A1 (en) 2016-03-25 2021-10-06 Intra-Cellular Therapies, Inc. Deuterated heterocyclic gamma-carboline compounds and their use in the treatment or prophylaxis of a central nervous system disorder
JP2019513143A (ja) 2016-03-28 2019-05-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規塩類および結晶
JP6997718B2 (ja) 2016-03-28 2022-01-18 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規共結晶
WO2018126143A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
MX2021013640A (es) 2017-03-24 2022-08-31 Intra Cellular Therapies Inc Composiciones novedosas y metodos.
JP7224333B2 (ja) 2017-07-26 2023-02-17 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
CA3071119A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. Organic compounds
EP3801527A4 (en) 2018-06-08 2022-03-30 Intra-Cellular Therapies, Inc. NEW METHODS
EP3833346A4 (en) 2018-08-08 2022-08-03 Torralva Medical Therapeutics LLC COMPOSITIONS FOR THE PREVENTION AND REVERSAL OF THE EFFECTS OF OPIATES AND OPIOIDS, AND METHODS OF USE THEREOF
WO2020132605A1 (en) 2018-12-21 2020-06-25 Intra-Cellular Therapies, Inc. Organic compounds
CN114126615A (zh) 2019-05-07 2022-03-01 尼萨姆实验室公司 阿片受体拮抗剂前药

Also Published As

Publication number Publication date
BR112018015283B1 (pt) 2023-09-26
MX2021010306A (es) 2021-10-13
ES2863471T3 (es) 2021-10-11
CN108883111B (zh) 2021-10-08
RU2018130727A3 (pl) 2020-03-13
WO2017132408A1 (en) 2017-08-03
JP2019503383A (ja) 2019-02-07
JP2022050417A (ja) 2022-03-30
EP3838274B1 (en) 2023-11-01
PT3838274T (pt) 2023-12-18
DK3407888T3 (da) 2021-04-06
IL260653B2 (en) 2023-03-01
AU2017211791B2 (en) 2022-01-06
KR20180099905A (ko) 2018-09-05
IL260653A (pl) 2018-09-20
US20170319580A1 (en) 2017-11-09
US20210060010A1 (en) 2021-03-04
RU2020134306A (ru) 2020-11-24
RU2020134306A3 (pl) 2022-01-13
EP3407888B1 (en) 2020-12-30
IL296884B1 (en) 2024-01-01
CN113786407A (zh) 2021-12-14
PL3838274T3 (pl) 2024-04-02
CN108883111A (zh) 2018-11-23
MX2018009158A (es) 2018-11-19
JP7234337B2 (ja) 2023-03-07
US20230181576A9 (en) 2023-06-15
DK3838274T3 (da) 2024-01-22
EP3407888A4 (en) 2019-06-26
IL260653B (en) 2022-11-01
US10245260B2 (en) 2019-04-02
JP2023075159A (ja) 2023-05-30
US11844757B2 (en) 2023-12-19
US20190175590A1 (en) 2019-06-13
JP7471482B2 (ja) 2024-04-19
RU2743513C2 (ru) 2021-02-19
EP3407888A1 (en) 2018-12-05
BR112018015283A2 (pt) 2018-12-18
EP3838274A1 (en) 2021-06-23
PT3407888T (pt) 2021-03-19
HUE053737T2 (hu) 2021-07-28
IL296884A (en) 2022-12-01
CA3011983A1 (en) 2017-08-03
IL309536A (en) 2024-02-01
AU2017211791A1 (en) 2018-08-16
US10799500B2 (en) 2020-10-13
RU2018130727A (ru) 2020-02-27
JP6995761B2 (ja) 2022-01-17

Similar Documents

Publication Publication Date Title
HUE053737T2 (hu) Piridopirrolokinoxalin vegyületek, készítményeik és alkalmazásaik
IL272089B1 (en) Compounds, preparations and methods
HUE062446T2 (hu) Vegyületek, készítmények és eljárások
EP3179870C0 (en) ANTIMICROBIAL COMPOUNDS AND COMPOSITIONS AND USES THEREOF
IL247319A0 (en) Triazine compound, preparations containing them and their uses
IL264446A (en) Compounds and compositions and their use
GB201715769D0 (en) Methods, Compositions and uses relating thereto
PT3552017T (pt) Compostos úteis como inibidores de ripk1
GB2560212B (en) Methods, compositions and uses relating thereto
GB2554485B (en) Methods, compositions and uses relating thereto
IL264445A (en) Compounds and compositions and their use
GB201513614D0 (en) Compositions, compounds and methods and uses relating thereto
GB2559645B (en) Methods, compositions and uses relating thereto
GB2559644B (en) Methods, compositions and uses relating thereto
GB2560213B (en) Methods, compositions and uses relating thereto
GB201715799D0 (en) Methods, compositions and uses relating thereto
IL270505B1 (en) Compounds, preparations and methods
IL255042A0 (en) Amphiphilic compounds, their preparations and uses
IL259900A (en) Aminoazole derivatives, compositions containing same and uses thereof
GB201616745D0 (en) Methods, compositions and uses relating thereto
GB201616746D0 (en) Methods, compositions and uses relating thereto
GB201616676D0 (en) Methods, compositions and uses relating thereto
GB201616645D0 (en) Methods, compositions and uses relating thereto
GB201616647D0 (en) Methods, compositions and uses relating thereto
GB201616648D0 (en) Methods, compositions and uses relating thereto